Abstract:
Objective: To determine the demographics and clinical outcomes of remission induction in Acute Myeloid Leukemia in settings with limited resources. Methodology: A retrospective study was conducted at the Department of Medical Oncology, Pakistan Institute of Medical Sciences (PIMS), Islamabad, from January 2005 to April 2022. A total of 334 patients with AML were reviewed for age, gender, address, HBV/HCV status, peripheral film, bone marrow biopsy, flow cytometry, gene markers, cytogenetics, treatment, and outcome. Data was analyzed using SPSS version 25. Results: AML was predominant in adults with a median age of 30, with 193 (57.8%) in the age group of 19-40 years, followed by 67 (20.1%) in the age group of 12-18 years, 58 (17.4%) in the age group of 41- 60 years, and 16 (4.8%) in elderly patients above 60 years of age. Males were affected more compared to females, accounting for 191 (57.2%) vs. 143 (42.8%). Patients from Punjab accounted for 150 (44.7%) of all cases, followed by AJK 75 (22.5%) and KPK 68 (20.4%). Among all 334 patients, 32 (9.6%) had white blood cells above 100,000, and 252 (75.4%) had more than 20% blasts in peripheral film. Out of 334 patients, 260 (77.8%) were diagnosed with AML, 72 (21.6%) with APML, and 2 (0.6%) with MPD transformed to AML. All patients received remission induction chemotherapy, and 93 patients died during induction, resulting in a treatment-related mortality (TRM) of 27.3%. Conclusion: Acute myeloid leukemia in the Pakistani population is seen in a relatively younger age group with male predominance, and overall induction-related mortality is high in our setup
Page(s):
81-84
DOI:
DOI not available
Published:
Journal: Journal of Haematology and Stem Cell Research, Volume: 2, Issue: 2, Year: 2022